A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5081 participants.

Also called NCT01877915

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,081 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01877915
  • EudraCT 2013-000046-19
Other papers using this trial's data
  • A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial European heart journal, 2019-11-21 DOI, PubMed 31461239, PMC6868495 In the PMC Open Access subset under CC BY-NC.
  • Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial JAMA cardiology, 2019-06-01 DOI, PubMed 31017637, PMC6487904 Not in the PMC Open Access subset.
  • Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF JACC. Heart failure, 2020-05 DOI, PubMed 32171760
  • Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease The New England journal of medicine, 2018-10-04 DOI, PubMed 30146935

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01877915. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-10 (actual); primary completion 2018-04-19 (actual). Results posted on 2019-05-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Acronym
COMMANDER HF
Condition
Heart Failure
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Placebo
Intervention (Other)
Standard of care for heart failure and coronary artery disease
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01877915
Content hash
b6c14f42f8fb274ddea5fddca4195a64fc739d400fc812e4189f78ce67f5d574